Relypsa (RLYP) : Traders are bullish on Relypsa (RLYP) as it has outperformed the S&P 500 by a wide margin of 10.64% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.97%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.48% in the last 1 week, and is up 15.48% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 11.56% and the 50-Day Moving Average is 18.52%.
Relypsa (NASDAQ:RLYP): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $20.02 and $19.81 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $20.85. The buying momentum continued till the end and the stock did not give up its gains. It closed at $20.67, notching a gain of 3.71% for the day. The total traded volume was 2,614,860 . The stock had closed at $19.93 on the previous day.
The company Insiders own 3.7% of Relypsa shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -34.03% . Institutional Investors own 81.47% of Relypsa shares. During last six month period, the net percent change held by insiders has seen a change of 71.72%. In a related news, The Securities and Exchange Commission has divulged that Torley Helen, director of Relypsa Inc, had unloaded 1,013 shares at an average price of $19.32 in a transaction dated on June 7, 2016. The total value of the transaction was worth $19,571.
Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The Companys lead product candidate, Patiromer for Oral Suspension (Patiromer FOS) is for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration, or FDA. The Companys NDA is supported by a clinical development program consisting of eight clinical trials: three Phase I trials, four Phase II trials and one two-part Phase III trial conducted under a Special Protocol Assessment, or SPA. The active ingredient is a cross-linked polymeric bead with a calcium containing counterion. The Company has the global royalty-free commercialization rights to Patiromer FOS.